Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Annovera DDI Study with Itraconazole and Rifampin
NCT04290390Phase 1Completed
- Sponsor
- TherapeuticsMD
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of segesterone in contraception (3 arms), sponsored by TherapeuticsMD. Primary endpoints: Area-under-the-curve of rifampin and itraconazole on Annovera at Day 11, Maximum concentration of rifampin and itraconazole on Annovera at Day 11 and 2 more. Started Feb 2020; status: completed.
02
Drugs
segesterone
03
Conditions
contraception
Beyond the preview
Go deeper on NCT04290390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04290390.